To the Editor,
The newly developed leadless self-contained right ventricular single-chamber pacemaker, implanted by percutaneous femoral access, represents a cutting-edge advancement in cardiac pacemaker technology. 1 Its presumed advantages include the avoidance of pocket and lead infections and pneumothorax during insertion. Nevertheless, femoral vascular complications and device dislodgement can happen. We present a case of a 78-yr-old patient with an indwelling Nanostim LCP (inserted in the US two years earlier after a prior conventional pacemaker caused tricuspid regurgitation) who presented for tricuspid valve replacement. He was cooled during cardiopulmonary bypass (CPB) to 31.2°C and was subsequently rewarmed to 36.5°C before CPB was discontinued. At that time, the ventricular paced rate suddenly increased to 120 beatsÁmin -1 As the electrophysiology (EP) service that was consulted to intraoperatively interrogate the device did not have equipment compatible with the Nanostim, a sterile magnet was applied to the apical surface of the heart to asynchronously pace at 90 beatsÁmin -1 This was changed to two magnets used to cover the ventricular apex as the contracting myocardium intermittently displaced the original single magnet. Postoperatively, the magnets were secured to the skin on the left anterolateral chest wall. A permanent epicardial lead was also inserted and tested intraoperatively to overdrive the Nanostim LCP.
In the intensive care unit, postoperative chest radiography confirmed that the Nanostim LCP had not moved and, when subsequently interrogated, had a rate of 60 beatsÁmin -1 . Therefore, temporary epicardial pacing wires were used to pace at 85 beatsÁmin -1 to optimize cardiac output. On the third postoperative day (POD), the device was interrogated by a company representative and found to be functioning nominally with the battery at 3.3 V and an estimated 5.7 years of battery life; thus, the epicardial pacing wires were removed. On POD 8 the patient was transferred to the ward without further pacemaker issues. This patient's Nanostim LCP had originally been placed as part of the LEADLESS pacemaker IDE study (clinical trials.gov; NCT02030418) during which 1,423 devices were implanted. 1, 4 This pacemaker features a heart rate modulation function based on blood temperature. 1, 2 It is likely that its temperature sensor was activated during rewarming from CPB and increased the paced rate to its upper limit of 120 beatsÁmin -1 in a temperature-sensitive pacemaker. In October 2016, the trial was paused by the manufacturer who recommended more intensive follow-up and device replacement for pacemaker-dependent patients 4 ; however, not all the patients have been followed up. Accordingly, patients with this leadless pacemaker might still present at various hospitals in different countries for unrelated procedures. It is therefore important to be familiar with leadless pacemakers as more advanced multicomponent leadless systems are expected to be implanted in the future. This case emphasizes the importance of preoperative assessment of unfamiliar devices and of a multidisciplinary intraoperative approach including ready access to EP services. Finally, preparation to use alternatives to guarantee uninterrupted pacemaker function in the case of an unreliable indwelling pacemaker is important.
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